Picture of Structure Therapeutics logo

GPCR — Structure Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSucker Stock

Structure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Structure Therapeutics Inc GPCR.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -54 cents.  The mean expectation of ten analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -32 cents to -22 cents per share.

Reported revenue was zero​; analysts expected zero.

Structure Therapeutics Inc's reported EPS for the quarter was a loss of 36 cents​.

The company reported a quarterly loss of $61.66 million.

Structure Therapeutics Inc shares had fallen by 21.4% this quarter and lost 39.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 12.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Structure Therapeutics Inc is $65.00, about 74.9% above its last closing price of $16.31

This summary was machine generated from LSEG data August 7 at 07:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
Jun. 30 2025-0.28-0.36Missed
Mar. 31 2025-0.23-0.81Missed
Dec. 31 2024-0.22-0.69Missed
Sep. 30 2024-0.19-0.60Missed

Recent news on Structure Therapeutics

See all news